July 1, 2013 / 11:26 AM / 4 years ago

Insmed's lung infection drug succeeds in late-stage trial

July 1 (Reuters) - Insmed Inc said a late-stage trial of its experimental lung infection drug showed the therapy was as effective as another approved treatment.

The drug, Arikace, was being tested as a treatment for a bacterial infection in cystic fibrosis patients. The trial met its main goal of showing Arikace was not inferior to Tovi, Novartis’s drug for the same infection.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below